Literature DB >> 16002044

Chondroitin sulfate addition to CD44H negatively regulates hyaluronan binding.

Brian Ruffell1, Pauline Johnson.   

Abstract

CD44 is a widely expressed cell adhesion molecule that binds hyaluronan, an extracellular matrix glycosaminoglycan, in a tightly regulated manner. This regulated interaction has been implicated in inflammation and tumor metastasis. CD44 exists in the standard form, CD44H, or as higher molecular mass isoforms due to alternative splicing. Here, we identify serine 180 in human CD44H as the site of chondroitin sulfate addition and show that lack of chondroitin sulfate addition at this site enhances hyaluronan binding by CD44. A CD44H-immunoglobulin fusion protein expressed in HEK293 cells, and CD44H expressed in murine L fibroblast cells were modified by chondroitin sulfate, as determined by reduced sulfate incorporation after chondroitinase ABC treatment. Mutation of serine 180 or glycine 181 in CD44H reduced chondroitin sulfate addition and increased hyaluronan binding, indicating that serine 180 is the site for chondroitin sulfate addition in CD44H and that this negatively regulates hyaluronan binding.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002044     DOI: 10.1016/j.bbrc.2005.06.108

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Regenerative potential of glycosaminoglycans for skin and bone.

Authors:  Juliane Salbach; Tilman D Rachner; Martina Rauner; Ute Hempel; Ulf Anderegg; Sandra Franz; Jan-Christoph Simon; Lorenz C Hofbauer
Journal:  J Mol Med (Berl)       Date:  2011-12-21       Impact factor: 4.599

Review 2.  CD44 and HCELL: preventing hematogenous metastasis at step 1.

Authors:  Pieter P Jacobs; Robert Sackstein
Journal:  FEBS Lett       Date:  2011-08-05       Impact factor: 4.124

3.  Identification and molecular analysis of glycosaminoglycans in cutaneous lupus erythematosus and dermatomyositis.

Authors:  Laura M Chang; Prateesh Maheshwari; Sheila Werth; Lana Schaffer; Steven R Head; Carrie Kovarik; Victoria P Werth
Journal:  J Histochem Cytochem       Date:  2011-01-12       Impact factor: 2.479

4.  Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in Inflammatory and Interleukin 4-activated Macrophages.

Authors:  Brian Ruffell; Grace F T Poon; Sally S M Lee; Kelly L Brown; Sie-Lung Tjew; Jessie Cooper; Pauline Johnson
Journal:  J Biol Chem       Date:  2011-04-06       Impact factor: 5.157

5.  Biomolecular characterization of CD44-fibrin(ogen) binding: distinct molecular requirements mediate binding of standard and variant isoforms of CD44 to immobilized fibrin(ogen).

Authors:  Christina S Alves; Sergiy Yakovlev; Leonid Medved; Konstantinos Konstantopoulos
Journal:  J Biol Chem       Date:  2008-11-11       Impact factor: 5.157

Review 6.  Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer.

Authors:  Suniti Misra; Vincent C Hascall; Roger R Markwald; Shibnath Ghatak
Journal:  Front Immunol       Date:  2015-05-06       Impact factor: 7.561

7.  CD44-mediated hyaluronan binding marks proliferating hematopoietic progenitor cells and promotes bone marrow engraftment.

Authors:  Sally S M Lee-Sayer; Meghan N Dougan; Jesse Cooper; Leslie Sanderson; Manisha Dosanjh; Christopher A Maxwell; Pauline Johnson
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

8.  Application of Collagen-Model Triple-Helical Peptide-Amphiphiles for CD44-Targeted Drug Delivery Systems.

Authors:  Margaret W Ndinguri; Alexander Zheleznyak; Janelle L Lauer; Carolyn J Anderson; Gregg B Fields
Journal:  J Drug Deliv       Date:  2012-11-14

9.  Transcriptional Profiling of Cultured, Embryonic Epicardial Cells Identifies Novel Genes and Signaling Pathways Regulated by TGFβR3 In Vitro.

Authors:  Daniel M DeLaughter; Cynthia R Clark; Danos C Christodoulou; Christine E Seidman; H Scott Baldwin; J G Seidman; Joey V Barnett
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.